ACA
Acorn Capital Advisors Portfolio holdings
AUM
$153M
1 Year Est. Return
–
AUM
$153M
AUM Growth
+$2.95M
(+2%)
Holding
22
Top Buys
| 1 | +$3.35M | |
| 2 | +$2.17M | |
| 3 | +$1.43M | |
| 4 |
YMAB
Y-mAbs Therapeutics
YMAB
|
+$828K |
| 5 |
Puma Biotechnology
PBYI
|
+$656K |
Top Sells
| 1 | +$3.88M | |
| 2 | +$3.51M | |
| 3 | +$1.52M | |
| 4 |
X4 Pharmaceuticals
XFOR
|
+$171K |
| 5 |
Cardiff Oncology
CRDF
|
+$106K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CG Oncology
CGON
$3.16B
| $29.4M | 19.24% |
1,131,501
|
|
||
2
UroGen Pharma
URGN
$921M
| $17.3M | 11.29% |
1,259,749
-256,554
|
|
||
|
YMAB
3
DELISTED
Y-mAbs Therapeutics
YMAB
| $15.4M | 10.09% |
3,418,995
+183,608
|
|
||
|
4
Puma Biotechnology
PBYI
$255M
| $14.2M | 9.27% |
4,131,299
+191,247
|
|
||
5
Candel Therapeutics
CADL
$287M
| $13.1M | 8.54% |
2,580,517
+428,265
|
|
||
6
Trevi Therapeutics
TRVI
$1.32B
| $11.7M | 7.67% |
2,144,844
|
|
||
7
Terns Pharmaceuticals
TERN
$1.32B
| $7.35M | 4.81% |
1,971,264
|
|
||
|
OKUR
8
OnKure Therapeutics
OKUR
$46M
| $6.79M | 4.44% |
2,839,674
+1,400,000
|
|
||
|
CYBN
9
Cybin
CYBN
$183M
| $6.16M | 4.03% |
734,394
|
|
||
|
BCAX
10
Bicara Therapeutics
BCAX
$854M
| $5.98M | 3.91% |
643,382
|
|
||
11
Protara Therapeutics
TARA
$190M
| $5.31M | 3.47% |
1,752,115
+472,315
|
|
||
|
12
Cardiff Oncology
CRDF
$151M
| $4.44M | 2.9% |
1,408,767
-33,541
|
|
||
13
Aura Biosciences
AURA
$373M
| $3.73M | 2.44% |
595,744
+5,236
|
|
||
14
Verastem
VSTM
$583M
| $3.23M | 2.12% |
779,498
|
|
||
|
WHWK
15
Whitehawk Therapeutics
WHWK
$104M
| $2.13M | 1.39% |
1,139,363
|
|
||
16
BioAtla
BCAB
$39.6M
| $1.91M | 1.25% |
4,835,111
+803,065
|
|
||
17
Mural Oncology
MURA
$36M
| $1.61M | 1.06% |
653,779
-615,936
|
|
||
18
VYNE Therapeutics
VYNE
$9.08M
| $1.22M | 0.79% |
736,572
-49,366
|
|
||
19
Q32 Bio
QTTB
$32.6M
| $1.2M | 0.78% |
803,425
|
|
||
20
Acrivon Therapeutics
ACRV
$68.9M
| $482K | 0.32% |
405,237
|
|
||
|
21
X4 Pharmaceuticals
XFOR
$317M
| $292K | 0.19% |
153,730
-89,958
|
|
||
|
OPTN
22
DELISTED
OptiNose
OPTN
| – | – |
-422,814
|
|